{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:18:45Z","timestamp":1787235525584,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.01.033","type":"journal-article","created":{"date-parts":[[2017,3,5]],"date-time":"2017-03-05T00:16:43Z","timestamp":1488673003000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation"],"prefix":"10.1016","volume":"76","author":[{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lasitschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf-Dieter","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Jentsch-Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Gr\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Gr\u00fcllich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2017.01.033_bib1","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/annonc\/mdp366","article-title":"High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors","volume":"21","author":"Lorch","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2017.01.033_bib2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1586\/era.10.231","article-title":"High-dose chemotherapy and stem cell transplantation for advanced testicular cancer","volume":"11","author":"Voss","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.ejca.2017.01.033_bib3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.eururo.2011.06.019","article-title":"Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and\/or multiply relapsed germ cell tumors","volume":"60","author":"Oechsle","year":"2011","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ejca.2017.01.033_bib4","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1093\/annonc\/mdr026","article-title":"Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group\/German Testicular Cancer Study Group cooperative study","volume":"22","author":"Oechsle","year":"2011","journal-title":"Ann Oncol"},{"issue":"(3","key":"10.1016\/j.ejca.2017.01.033_bib5","first-page":"e17","article-title":"Phase II study of everolimus in refractory testicular germ cell tumors","volume":"34","author":"Mego","year":"2016","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.01.033_bib6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejso.2013.09.019","article-title":"Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis","volume":"40","author":"Gandaglia","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.01.033_bib7","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/bjc.2013.117","article-title":"Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer","volume":"108","author":"Quezada","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2017.01.033_bib8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/phar.1714","article-title":"PD-1 pathway inhibitors: immuno-oncology agents for restoring antitumor immune responses","volume":"36","author":"Medina","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.ejca.2017.01.033_bib9","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/annonc\/mdw146","article-title":"Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors","volume":"27","author":"Zschabitz","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2017.01.033_bib10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1158\/2326-6066.CIR-16-0087","article-title":"Clinical response of a patient to anti-PD-1 immunotherapy and the immune landscape of testicular germ cell tumors","volume":"4","author":"Shah","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.ejca.2017.01.033_bib11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2017.01.033_bib12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2017.01.033_bib13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/annonc\/mdv574","article-title":"Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors","volume":"27","author":"Cierna","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.01.033_bib14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.ejca.2017.01.033_bib15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","article-title":"Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial","volume":"2","author":"George","year":"2016","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2017.01.033_bib16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2017.01.033_bib17","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T17:24:24Z","timestamp":1535995464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917307153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":17,"alternative-id":["S0959804917307153"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.033","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}